Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Avascular Necrosis Industry?

The market for avascular necrosis has seen robust growth in the past few years. The market will escalate from $0.81 billion in 2024 to $0.89 billion in 2025, marking a compound annual growth rate (CAGR) of 9.7%. The augmentation in historical periods can be credited to factors such as a growing elderly population, upsurge in alcohol intake, advancements in sports medicine, burgeoning medical tourism, and expansion in precision medicine.

In the coming years, it is predicted that the market size for avascular necrosis will experience considerable growth, and it is anticipated to expand to a value of $1.27 billion in 2029. The rate of growth is expected to be a compound annual growth rate (CAGR) of 9.3%. This trend of growth during the forecast period is due to a surge in the occurrence of corticosteroid-related osteonecrosis, an increase in knee and hip replacement surgeries, more approvals of drugs, a rise in the number of road accidents, and a growing number of bone injury cases. Major trends that will appear during the forecast period include technological advancements such as high-tech imaging technologies, diagnostic tools based on artificial intelligence, surgical implants made through 3D printing, regenerative orthobiologics, and cell therapies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24476&type=smp

What Forces Are Driving The Growth Of The Avascular Necrosis Industry?

The escalation in knee replacement and hip surgeries brought on by avascular necrosis is projected to magnify the expansion of the avascular necrosis market in the future. These corrective procedures involve the replacement of impaired joints inflicted by severe instances of avascular necrosis in order to alleviate pain. Aging and the increasing rates of osteoarthritis, which often lead to significant pain in the joints and movement issues, necessitate surgical aid for respite and enhancement of life quality. Knee replacement and hip surgery demands surge because of avascular necrosis, the medical condition that triggers the death of bone tissues due to deficiency in blood supply, often leading to the malfunction and disintegration of joints. As per Curvo Labs, Inc., an American healthcare technology firm, in September 2023, the count of knee replacement operations in the U.S. rose from 1,235,835 in 2021 to 1,299,084 in 2022. Therefore, the surging demand for knee replacements and hip surgeries bolsters the growth of the avascular necrosis market. The increasing costs dedicated to healthcare is anticipated to facilitate the growth of the avascular necrosis market in the future. Healthcare expenditure encompasses the consolidated sum invested in health services, treatments, and medicinal goods within a particular demographic or healthcare system. The spending on healthcare is escalating due to the rising occurrence of chronic illnesses which necessitate long-term supervision, recurrent hospital visits, and expensive prescriptions. This expenditure proves beneficial for avascular necrosis by offering access to prompt diagnosis, state-of-the-art treatments, and surgeries that aid in managing the ailment and enhancing patient survival. The American Medical Association, an American professional and lobbying organization comprised of physicians and medical students, reported in April 2025 that health expenditure in the United States jumped by 7.5% in 2023, reaching a total of $4.9 trillion, or $14,570 per person which is greater than the 4.6% growth rate in 2022. Hence, the rising healthcare expenditure is fuelling the growth of the avascular necrosis market.

What Is The Overview Of Market Segmentation In The Avascular Necrosis Industry?

The avascular necrosis market covered in this report is segmented –

1) By Type: Trauma Related Avascular Necrosis, Non-Trauma Related Avascular Necrosis

2) By Diagnosis: Imaging, Biopsy, Computed Tomography Scan, Positron Emission Tomography, X-Ray

3) By Treatment Type: Medications, Surgery, Physical Therapy, Lifestyle Changes, Bone Grafting

4) By End-User: Hospitals, Specialty Clinics, Rehabilitation Centers, Ambulatory Surgical Centers, Home Care Settings

Subsegment:

1) By Trauma-Related Avascular Necrosis: Fracture-Induced Avascular Necrosis, Dislocation-Induced Avascular Necrosis, Post-Surgical Avascular Necrosis, Crush Injury-Related Avascular Necrosis, Sports Injury-Associated Avascular Necrosis

2) By Non-Trauma Related Avascular Necrosis: Steroid-Induced Avascular Necrosis, Alcohol-Induced Avascular Necrosis, Sickle Cell Disease-Associated Avascular Necrosis, Lupus-Related Avascular Necrosis, Radiation Therapy-Induced Avascular Necrosis, Idiopathic Avascular Necrosis

What Future Market Trends Are Projected For The Avascular Necrosis Industry?

In the avascular necrosis market, dominant corporations are striving for regulatory authorizations to broaden their product range, improve treatment alternatives and solidify their market influence. Regulatory authorizations are official authorizations bestowed by health authorities, permitting a medical product or treatment to be marketed and implemented upon satisfying safety and efficacy requirements. For example, in May 2022, an approval was granted by the United States Food and Drug Administration to Regrow Biosciences, a biotechnology organization based in India. This allowed them to operate Phase II clinical examinations in the US for their orphan drug OSSGROW, used for the treatment of osteonecrosis, also known as avascular necrosis. OSSGROW, a cutting-edge personalized bone cell therapy system, was developed for the curative treatment of early to moderate (up to Stage III) avascular necrosis (AVN) by Regrow Biosciences. The therapy utilizes the patient’s bone marrow, wherein mesenchymal stem cells are cultivated and morphed into osteoblasts, cells that form bones, through a specialized laboratory process. OSSGROW is considered a natural, secure, and potentially permanent solution, intending to substitute traditional treatments and joint replacement surgeries that only manage symptoms.

Who Are The Primary Players Operating Across The Global Avascular Necrosis Market?

Major companies operating in the avascular necrosis market are Stryker Corporation, Massachusetts General Hospital, Zimmer Biomet Holdings Inc., Smith & Nephew plc, Stanford Health Care, Apollo Hospitals Enterprise Limited, Singapore General Hospital Pte Ltd., Fortis Healthcare Limited, Narayana Hrudayalaya Limited, Bumrungrad International Hospital Co. Ltd., Aster DM Healthcare Limited, Mount Elizabeth Hospital Pte Ltd., Gleneagles Hospital Pte Ltd., Shalby Limited, Texas Orthopedic Hospital LLC, Regrow Biosciences Pvt. Ltd., Maxcure Hospitals Limited, Medicover Hospitals Private Limited, Mesoblast Limited, Athersys Inc., Ginger Healthcare Private Limited

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/avascular-necrosis-global-market-report

Which Region Offers The Most Growth Potential For The Avascular Necrosis Market Through 2029?

North America was the largest region in the avascular necrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the avascular necrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24476&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model